Active, not recruitingPhase 4NCT06101095
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Studying NON RARE IN EUROPE: Eosinophilic esophagitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Dupilumab(drug)
- Enrollment
- 69 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- United Gastroenterologists - Murrieta- Site Number : 8400001, Murrieta, California, United States
- University of California San Francisco - Parnassus Heights- Site Number : 8400020, San Francisco, California, United States
- Borland Groover Clinic- Site Number : 8400016, Jacksonville, Florida, United States
- Treasure Valley Medical Research- Site Number : 8400018, Boise, Idaho, United States
- Northwestern University- Site Number : 8400003, Chicago, Illinois, United States
- GI Alliance - Glenview- Site Number : 8400012, Glenview, Illinois, United States
- Illinois Gastroenterology Group- Site Number : 8400004, Gurnee, Illinois, United States
- University of Iowa- Site Number : 8400006, Iowa City, Iowa, United States
- University of Massachusetts Chan Medical School- Site Number : 8400019, Worcester, Massachusetts, United States
- Mayo Clinic Hospital Rochester- Site Number : 8400008, Rochester, Minnesota, United States
- University of North Carolina at Chapel Hill- Site Number : 8400007, Chapel Hill, North Carolina, United States
- Cleveland Clinic - Cleveland- Site Number : 8400009, Cleveland, Ohio, United States
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010, Philadelphia, Pennsylvania, United States
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015, Houston, Texas, United States
- GI Alliance - Mansfield- Site Number : 8400017, Mansfield, Texas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Regeneron Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06101095 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Eosinophilic esophagitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07112378A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRegeneron Pharmaceuticals
- RECRUITINGNCT07156357Surface EMG Testing on Swallowing in EoE PatientsMayo Clinic
- RECRUITINGNCT06972147Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic EsophagitisUniversity Hospital, Angers
- RECRUITINGNCT07012928Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II InflammationAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- RECRUITINGPHASE2NCT05485155Zemaira Eosinophilic Esophagitis Pilot StudyChildren's Hospital Medical Center, Cincinnati
- ENROLLING BY INVITATIONNANCT06756581Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein TriggerShaare Zedek Medical Center
- RECRUITINGPHASE2NCT06705387Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoEUniversity of Colorado, Denver
- RECRUITINGNCT06693531A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of CareRegeneron Pharmaceuticals
See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis →